Directory of Clinical Research Networks In Singapore

Many clinical research networks have been established in Singapore. They share a common goal in providing research infrastructure to support high quality clinical research. Please contact the respective personnel if you are interested in any of the clinical research network listed in the directory below:

Clinical Research Networks in SingaporeContacts

The Cancer Therapeutics Research Group (CTRG) was formed in October 1997 by Professor John Wong (National University Health System) and Professor James Bishop (Sydney Cancer Centre and University of Sydney) to develop new therapeutic strategies for cancers common to Asia-Pacific.

This resulted in a joint research group which performs clinical trials on new anti-cancer drugs in Asia-Pacific, and aims to be the equivalent of oncology cooperative groups in the USA.

The CTRG has rapidly established itself and is now recognised as the leading group for evaluating new therapeutic strategies in the Asia-Pacific region.

Ms Joan Phee
Email: joan_phee@nuhs.edu.sg
Website: Click here

Clinical Research Networks in SingaporeContacts

DevOS is the Translational Clinical Research (TCR) Flagship Programme on Developmental Pathways to Health and Disease: Metabolic, Neurodevelopmental and Related Outcomes.

Dr Iris Shen Zhe
Email: obgszi@nus.edu.sg  
Phone: +65 6601 1943
Website: www.devos.sg

Clinical Research Networks in SingaporeContacts

The Haematology-Oncology Research Group Trial Unit is led by Ms. Joanne Chio, comprising a dedicated team of clinical research coordinators, data managers and administrators. The HORG trial unit manages and supports all aspects of the clinical trial: from securing the ethics and regulatory approval to the conduct of the study. At present, the unit is conducting 62 clinical trials with quite a number of Phase I and II studies.

Ms Joan Phee
Email: Joan_phee@nuhs.edu.sg 
Phone: +65 6772 2404
Website: Click here

Clinical Research Networks in SingaporeContacts

The Singapore Gastric Cancer Consortium (SGCC) is a translational research group comprising clinicians and scientists working in gastric cancer research.  The group aims to solve important clinical questions to improve the care of gastric cancer patients, facilitated by close interaction between clinicians and scientists, and with synergism that enables biologic discoveries in the laboratory to be validated in the clinical setting.

Key research projects include risk susceptibility studies, biomarker discovery and validation, the genetic mapping of gastric cancer and clinical trials of novel treatment agents.

In July 2007, the consortium was awarded the first Translational and Clinical Research (TCR) Flagship Research Grant by the National Research Foundation (NRF) of Singapore. A five-year renewal was subsequently awarded to the consortium for 2013-2018.

Email: sgcc_admin@nus.edu.sg
Website: www.sgcc.sg

Clinical Research Networks in SingaporeContacts

Singapore Infectious Diseases Clinical Research Network (SCRN) is funded by the Ministry of Health, Singapore through Singapore Infectious Diseases Initiative and hosted by Tan Tock Seng Hospital. The network aims to engage local infectious diseases clinicians in a collaborative approach to spearhead cross-institutional clinical trials in Singapore.

Currently, the network assists in the coordination of 3 multi-center clinical trials and 1 clinical study in various tertiary-setting hospitals, including Tan Tock Seng Hospital, National University Hospital, and Singapore General Hospital. The 3 clinical trials involve comparing the efficacy of:

  • Early step-down to oral antibiotics versus intravenous antibiotics in patients with Klebsiella pneumonialiver abscess (AKLASS);
  • Vancomycin versus daptomycin for the treatment of methicillin-resistantStaphylococcus aureusbacteremia (MRSA); and
  • Combinational antibiotics treatment (Polymyxin B and doripenem) versus single antibiotics treatment (only Polymyxin B) for serious infections caused by extensively drug-resistant Gram-negative bacteria (XDR-GNB).

The clinical study involves defining the local epidemiology of carbapenem-resistant Enterobacteriaceae (CRE) and the associated mortality and morbidity (CaPES).

Dr Ding Ying
Network Coordinator
Email: Ying_Ding@ncid.sg

Clinical Research Networks in SingaporeContacts

Our research group draws together a national and international team comprising of basic scientists and clinicians with expertise in molecular epidemiology, next-generation sequencing, molecular pathology, bioinformatics and clinical trials. Importantly, our research also complements a nationwide genomic profiling program POLARIS (Personalised OMIC Lattice for Advanced Research and Improving Stratification). Consistent with the mission of POLARIS, we aim to administer the right therapies to the right patients at the right time. Our goal is to establish collaborations and synergy across all levels in Singapore so as to maximize resources and to increase the likelihood of significant success in realizing Singapore’s goal as a biomedical hub.

Our team’s overarching aim is to address pressing clinical challenges faced by clinicians worldwide in treating T- and NK/T-cell NHL through:

  1. Performing integrated genomic profiling to identify driving mutations/translocations, pathogens, and genetic susceptibility in T- and NK/T-cell NHL.
  2. Identifying novel diagnostic, prognostic and therapeutic targets of T- and NK/T-cell NHL through functional studies driven by genomic discoveries.
  3. Developing the basis for rational, targeted molecular therapy in T- and NK/T-cell NHL.

A/Prof Lim Soon Thye
Email: dmolst@nccs.com.sg
Phone: +65 6436 8000
Website: Work in progress

Clinical Research Networks in SingaporeContacts

SPRINT-TB is a translational bench-to-bedside tuberculosis (TB) research programme based at National University Health System (NUHS), Singapore. The programme spans research themes from mycobacterial target identification and drug discovery to clinical development and treatment delivery. The clinical research aspect of the programme is focused on investigating new TB drug regimens, as well as evaluating novel compounds (including first-in-man studies) and licensed drugs for novel applications.

The programme currently runs multiple investigator-initiated Phase2/3 clinical trials and collaborates in pharmaceutical industry trials. The network closely works with most of key hospitals in Singapore, as well as with TB clinical sites in eight Asian countries. It has capabilities to conduct trials in large numbers of TB patients or healthy volunteers. The network has access to state-of-the-art infrastructure such as a full BSL-3 laboratory with a range of TB clinical research expertise, clinical research imaging facilities, genomics and immunomonitoring services, among many others.

Website: www.sprinttb.org